Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-021-03461-y http://scihub22266oqcxt.onion/10.1038/s41586-021-03461-y 33767445!ä!33767445 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2021 ; 593 (7859): 424-428 Nephropedia Template TP {{tp|p=33767445|t=2021. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice |pdf=|usr=}}{{33767445}} gab.com Text Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=33767445 #FOAvip Neutralizing antibodies that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein are among the most promising approaches against COVID-19(1,2). A bispecific IgG1-like molecule (CoV-X2) has been developed on the basis of C121 and C135, two antibodies derived from donors who had recovered from COVID-19(3). Here we show that CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable spike binding to the cellular receptor of the virus, angiotensin-converting enzyme 2 (ACE2). Furthermore, CoV-X2 neutralizes wild-type SARS-CoV-2 and its variants of concern, as well as escape mutants generated by the parental monoclonal antibodies. We also found that in a mouse model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, the simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, and combines the advantages of antibody cocktails with those of single-molecule approaches. Twit Text FOAVip Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=33767445 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33767445 #FOAvip English Wikipedia <ref>{{Cite pmid|33767445}}</ref> Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice #MMPMID33767445 De Gasparo R; Pedotti M; Simonelli L; Nickl P; Muecksch F; Cassaniti I; Percivalle E; Lorenzi JCC; Mazzola F; Magri D; Michalcikova T; Haviernik J; Honig V; Mrazkova B; Polakova N; Fortova A; Tureckova J; Iatsiuk V; Di Girolamo S; Palus M; Zudova D; Bednar P; Bukova I; Bianchini F; Mehn D; Nencka R; Strakova P; Pavlis O; Rozman J; Gioria S; Sammartino JC; Giardina F; Gaiarsa S; Pan-Hammarstrom Q; Barnes CO; Bjorkman PJ; Calzolai L; Piralla A; Baldanti F; Nussenzweig MC; Bieniasz PD; Hatziioannou T; Prochazka J; Sedlacek R; Robbiani DF; Ruzek D; Varani L Nature 2021[May]; 593 (7859): 424-428 PMID33767445show ga Neutralizing antibodies that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein are among the most promising approaches against COVID-19(1,2). A bispecific IgG1-like molecule (CoV-X2) has been developed on the basis of C121 and C135, two antibodies derived from donors who had recovered from COVID-19(3). Here we show that CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable spike binding to the cellular receptor of the virus, angiotensin-converting enzyme 2 (ACE2). Furthermore, CoV-X2 neutralizes wild-type SARS-CoV-2 and its variants of concern, as well as escape mutants generated by the parental monoclonal antibodies. We also found that in a mouse model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, the simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, and combines the advantages of antibody cocktails with those of single-molecule approaches. |Angiotensin-Converting Enzyme 2/antagonists & inhibitors/genetics/metabolism[MESH] |Animals[MESH] |Antibodies, Bispecific/*immunology/therapeutic use[MESH] |Antibodies, Monoclonal/immunology[MESH] |Antibodies, Neutralizing/*immunology/therapeutic use[MESH] |Body Weight[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*immunology/prevention & control/*virology[MESH] |Dependovirus/genetics[MESH] |Disease Models, Animal[MESH] |Epitopes, B-Lymphocyte/chemistry/immunology[MESH] |Female[MESH] |Humans[MESH] |Immune Evasion/genetics[MESH] |Immunoglobulin G/*immunology[MESH] |Mice[MESH] |Mice, Inbred C57BL[MESH] |SARS-CoV-2/genetics/*immunology[MESH]Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in (epmc).pdf DeepDyve Pubget Overpricing